CO2021004681A2 - Use of reboxetine for the treatment of narcolepsy - Google Patents

Use of reboxetine for the treatment of narcolepsy

Info

Publication number
CO2021004681A2
CO2021004681A2 CONC2021/0004681A CO2021004681A CO2021004681A2 CO 2021004681 A2 CO2021004681 A2 CO 2021004681A2 CO 2021004681 A CO2021004681 A CO 2021004681A CO 2021004681 A2 CO2021004681 A2 CO 2021004681A2
Authority
CO
Colombia
Prior art keywords
narcolepsy
reboxetine
treatment
cataplexy
human
Prior art date
Application number
CONC2021/0004681A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CO2021004681A2 publication Critical patent/CO2021004681A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se describen métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.Described herein are methods for the treatment of cataplexy narcolepsy, comprising administering reboxetine to a human in need of it. Reboxetine can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions for using the pharmaceutical composition to treat cataplexy narcolepsy in a human.

CONC2021/0004681A 2018-10-15 2021-04-14 Use of reboxetine for the treatment of narcolepsy CO2021004681A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
CO2021004681A2 true CO2021004681A2 (en) 2021-06-21

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0004681A CO2021004681A2 (en) 2018-10-15 2021-04-14 Use of reboxetine for the treatment of narcolepsy

Country Status (16)

Country Link
EP (1) EP3866768A4 (en)
JP (1) JP2022504975A (en)
KR (1) KR20210071046A (en)
CN (1) CN112888430A (en)
AU (2) AU2019361915A1 (en)
BR (1) BR112021007019A2 (en)
CA (1) CA3115983A1 (en)
CL (1) CL2021000924A1 (en)
CO (1) CO2021004681A2 (en)
CR (1) CR20210514A (en)
EC (1) ECSP21031200A (en)
IL (1) IL282311A (en)
MX (1) MX2021004207A (en)
PE (1) PE20211199A1 (en)
SG (1) SG11202103588WA (en)
WO (1) WO2020081461A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (en) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
KR20070029740A (en) * 2004-06-09 2007-03-14 화이자 인코포레이티드 Use of reboxetine for the treatment of pain
AU2014248849B2 (en) * 2013-03-13 2018-08-30 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy

Also Published As

Publication number Publication date
CA3115983A1 (en) 2020-04-23
CL2021000924A1 (en) 2021-09-03
KR20210071046A (en) 2021-06-15
CN112888430A (en) 2021-06-01
PE20211199A1 (en) 2021-07-01
ECSP21031200A (en) 2021-05-31
SG11202103588WA (en) 2021-05-28
IL282311A (en) 2021-05-31
WO2020081461A1 (en) 2020-04-23
AU2023200917A1 (en) 2023-03-23
JP2022504975A (en) 2022-01-13
BR112021007019A2 (en) 2021-07-13
AU2019361915A1 (en) 2021-05-13
MX2021004207A (en) 2021-08-11
EP3866768A4 (en) 2022-01-05
CR20210514A (en) 2021-11-12
EP3866768A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CO2021004681A2 (en) Use of reboxetine for the treatment of narcolepsy
DOP2023000187A (en) ANTIBODIES TARGETTING HIV GP120 AND METHODS OF USE
DOP2019000180A (en) INHIBITORS OF TGFß1 ISOFORM-SPECIFIC CONTEXT-PERMISIVES AND USE OF THE SAME
CL2017002996A1 (en) Tetra-substituted alkene compounds and their use
CL2018000818A1 (en) Oligonucleotide composition; methods to alter the junction of a white transcript; and use of the composition to treat duchenne muscular dystrophy.
CL2022001743A1 (en) Gamma-Hydroxybutyrate (GHB) Dosage
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
BR112016027773A2 (en) cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein
GT201700246A (en) METHODS AND KITS TO TREAT DEPRESSION
CL2008001268A1 (en) Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain.
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
CO2021015793A2 (en) Methods of treating or preventing asthma by administering an il-33 antagonist
BR112023005160A2 (en) COMBINATION THERAPY FOR THE TREATMENT OF CANCER
CL2021001976A1 (en) Treatment of skin lesions and pruritus in patients with nodular prurigo
MX2020004513A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
BR112019004540A2 (en) method for treating dementia in a patient, pharmaceutical composition, method for treating dementia in a patient, method for reducing the likelihood of developing dementia in a patient, composition for use in treating dementia in a patient, composition and composition for use in reducing dementia likelihood of developing dementia in a patient undergoing long therapy with a non-steroidal anti-inflammatory drug or aspirin
CL2022001079A1 (en) Methods and compositions for the treatment of rett syndrome
BR112019001082A2 (en) levodopa and carbidopa intestinal gel and methods of use
AR122344A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
UY39257A (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND ITS USE
CL2022001476A1 (en) Use of reboxetine to treat disorders of the nervous system
PE20230181A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
CL2019003288A1 (en) A pharmaceutical combination for the treatment of cancer.
BR112018014771A2 (en) composition comprising algal proteoglycan extract and its use
AR112535A1 (en) METHODS FOR THE TREATMENT OF TNFa-RELATED DISEASES